EPOS-Iasis is engaged in cutting-edge research in the field of molecular diagnostics and therapeutics. Current research projects include:

• Next-generation theranostics of brain pathologies with autonomous externally controllable nanonetworks: a trans-disciplinary approach with bionanodevice interfaces (FET Open GLADIATOR)
• A Fully Autologous Cell-based System for Delivery of Molecular Therapeutics to Brain Malignancies (BRAINTHROUGH)

For more information regarding each project, please visit the Current Research Activity page ...

In the past, EPOS-Iasis was involved in

• Management of Resistance to Tyrosine Kinase Inhibitors with Advanced Nanosystems (NANORESISTANCE IAPP)
• Molecular Markers of Antineoplastic Efficacy of Chromanol Esters
• Molecular Response Biomarkers of Multipotent Cyanine-Quinazoline Conjugates With Combined Imaging and Therapeutic Properties
• Novel Vitamin E-Biphosphonates: A new therapeutic approach targeting bone loss associated with osteoporosis and bone related malignancies
• New Generation of Fluorescent Contrast Agents for Inflammatory Bowel Disease and Colorectal Cancer
• EPIC-PANACEA: From Molecular Epidemiology to Molecular Imaging

For more information regarding each project, please visit the Past Research Activity page ...

EPOS-Iasis actively collaborates with a wide network of local and international partners. These collaborations enhance and compliment the company's expertise through biderectionally beneficial relationships. Collaborators include:

• University of Cyprus, Cyprus
  • Theodora Krasia, PhD, Dept. of Mechanical and Manufacturing Engineering
  • Demetris Tzeranis , PhD, Dept. of Mechanical and Manufacturing Engineering
  • Triantafyllos Stylianopoulos, PhD, Dept. of Mechanical and Manufacturing Engineering
• Biomedical Research Foundation of the Academy of Athens, Greece
  • Nicolaos Kostomitsopoulos, Dept. of Experimental Surgery
• Nicosia General Hospital, Cyprus
  • Ioanna Zouvani, Histopathology Department
  • Haralambos Andreou, Dept of Surgery
• University of Adelaide, Australia
  • Dr. Andreas Evdokiou, Bone Cancer Research Group
• University College London, School of Pharmacy
  • Dr. K. Kostarelos, Nanomedicine Lab
• Democritus University of Thrace
  • Dr. B. Agianian, Mol. Biology and Genetics
• Université Pierre et Marie Curie
  • Dr. Jean-Michel Siaugue, Colloïdes et Sciences Analytiques (PECSA)
• PROACTINA SA
  • Dr. Alexandros Strongilos, Bio-organic Synthesis

EPOS-Iasis has recently established a state-of-the art Biotechnology and Nanobiotechnology Laboratory building the interface between industrial and academic research in Molecular Optical Imaging. The available infrastructure includes access to a cryopreserved human tissue collection facility, securing the development and assessment of the tissue phantoms and cultures, high biosafety level tissue processing and culture facilities, advanced cellular and molecular biology systems (e.g. protein and nucleic acids analysis systems; spectrofluorimager connected to image direct documentation systems), immunohistochemistry platforms, and Fluorescent Microscopes.

Access is further provided to a recently upgraded synthetic facility, a platform of local and international collaboration, equipped with Atomic Force and Electron Microscopes; NMR, HPLC, GC – MSpectroscopy, UV, IR and Atomic Absorption Spectrophotemeters, potensiostands, polisimeters, and open chromatography columns .

Through its Section on Optics Research, EPOS-Iasis has established basic optical and fiberoptic laboratory with prototyping components, optomechanical equipment, ultra-high precision positioning and scanning devices, light sources (HeNe, Tungsten, Ti:Sapphire, and optical sources), detectors, signal generation and acquisition devices.

Back To Top

For more information contact:

Dr. Andreani Odysseos (andreani[at]epos-iasis.com)